Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Cohn-Cedermark G, Stahl O, Tandstad T; SWENOTECA. Andrology. 2014 Oct 1. doi: 10.1111/andr.280. [Epub ahead of print] Although clinical stage I (CS I) testicular cancer is highly curable, the optimal management is controversial. The aims of the SWENOTECA studies for CS I non-seminoma (NS) and seminoma (S) have been to reduce treatment intensity while maintaining hi

In the last months several new articles have been published by or in collaboration with SWENOTECA . One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group. Ann Oncol. 2014 Aug 11. pii: mdu375. [Epub ahead of print] Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; on behalf of

A new protocol for seminoma is now available. It replaces SWENOTECA VII from October 1, 2014. The major changes in the guideline are: Stage I: Patients with tumour size 4 cm or less and without invasion of the rete testis are recommended surveillance. Patients with tumour size more than 4 cm or invasion of the rete testis are recommended adjuvant carboplatin. Surveillance may be an option to those patients not wanting adjuvant treatment. Stage II A ​Chemotherapy in the form